Zealand Pharma A/S (CPH:ZEAL)

Zealand Pharma Balance Sheet

Financials in millions DKK. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4,038	4,577	726.03	449.31	1,069	1,129
Trading Asset Securities	10,419	10,532	7,500	1,184	108.61	299.04
Cash & Short-Term Investments	14,457	15,109	8,226	1,633	1,178	1,428
Cash Growth	-12.79%	83.67%	403.72%	38.65%	-17.53%	13.56%
Accounts Receivable	3,816	174.21	87.17	97.8	115.62	153.45
Other Receivables	118	145.47	97.44	40.99	21.6	21.56
Receivables	3,934	319.69	184.61	138.8	137.22	175.02
Inventory	-	-	10.7	7.94	1.29	118.44
Prepaid Expenses	299	241.62	106.39	-	-	-
Total Current Assets	18,690	15,670	8,528	1,780	1,316	1,722
Property, Plant & Equipment	168	151.43	125.25	149.85	165.49	221.45
Long-Term Investments	-	-	819.63	21.38	37.84	26.91
Other Intangible Assets	839	44.97	12.62	12.26	-	53.79
Long-Term Accounts Receivable	-	-	-	6.89	18.11	29.09
Long-Term Deferred Tax Assets	1	0.87	0.99	0.93	2.02	13.53
Other Long-Term Assets	64	81.41	19.41	8.91	-	1.27
Total Assets	19,762	15,949	9,506	1,980	1,540	2,068

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	144	256.62	181.28	91.61	180.76	266.39
Accrued Expenses	98	114.57	93.66	51.73	-	-
Current Portion of Leases	29	22.63	16.04	16.66	14.73	14.9
Current Income Taxes Payable	87	-	-	-	-	-
Current Unearned Revenue	12	65.34	-	-	-	53.03
Other Current Liabilities	967	205.8	112.5	124.59	-	-
Total Current Liabilities	1,337	664.97	403.47	284.58	195.49	334.32
Long-Term Debt	312	302.92	285.33	-	401.35	647.91
Long-Term Leases	70	80.21	90.39	102.58	108	124.63
Long-Term Unearned Revenue	-	-	-	-	-	14.55
Other Long-Term Liabilities	43	70.08	109.67	-	19.06	18.43
Total Liabilities	1,762	1,118	888.86	387.15	723.9	1,140

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	72	71.52	71.02	58.75	51.7	43.63
Additional Paid-In Capital	14,741	14,729	14,681	6,406	4,921	-
Retained Earnings	3,165	6.29	-6,157	-4,895	-4,172	-
Comprehensive Income & Other	22	23.38	22.39	22.7	14.62	884.17
Shareholders' Equity	18,000	14,831	8,617	1,593	815.91	927.8
Total Liabilities & Equity	19,762	15,949	9,506	1,980	1,540	2,068

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	411	405.77	391.76	119.23	524.08	787.43
Net Cash (Debt)	14,046	14,703	8,654	1,514	653.77	640.72
Net Cash Growth	-13.19%	69.90%	471.66%	131.55%	2.04%	-43.17%
Net Cash Per Share	197.47	205.50	130.26	26.75	14.15	14.95
Filing Date Shares Outstanding	69.34	70.61	70.65	58.38	51.47	43.22
Total Common Shares Outstanding	69.34	70.61	70.65	58.38	51.47	43.22
Working Capital	17,353	15,005	8,124	1,495	1,121	1,387
Book Value Per Share	259.59	210.04	121.96	27.28	15.85	21.47
Tangible Book Value	17,161	14,786	8,604	1,581	815.91	874.01
Tangible Book Value Per Share	247.49	209.41	121.78	27.07	15.85	20.22
Machinery	-	108.22	84.91	78.57	82.83	106.63
Construction In Progress	-	-	-	-	0.87	12.11
Leasehold Improvements	-	41.52	39.3	38.91	38.19	36.6

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 29, 2026

Data Sources Report a data error